Sarepta Awards $125,000 in Duchenne Scholarships for 2026-2027 Academic Year — Sarepta Therapeutics, Inc.

Event summary

Sarepta awarded 25 scholarships totaling $125,000 for the 2026-2027 academic year through its Route 79 program.
20 scholarships went to individuals living with Duchenne muscular dystrophy, and 5 to siblings of affected individuals.
The program, now in its ninth year, expanded in 2022 to include siblings of Duchenne patients.
Recipients were selected by an independent committee based on academic record, community involvement, personal essays, and recommendation letters.
Scholarship amounts are up to $5,000 per student.

The big picture

Sarepta's Route 79 scholarship program represents a strategic investment in the Duchenne community, reinforcing the company's commitment to patients beyond therapeutic development. This initiative aligns with broader industry trends of pharmaceutical companies engaging in meaningful corporate social responsibility efforts to build trust and demonstrate long-term value to stakeholders. The program's expansion to include siblings acknowledges the broader family impact of rare diseases, potentially setting a precedent for similar initiatives in the biotech sector.

What we're watching

Program Expansion: Whether Sarepta will continue expanding the Route 79 program to include more siblings or other family members in future years.
Impact Measurement: How Sarepta will track and report the long-term impact of these scholarships on educational attainment and career outcomes for recipients.
Corporate Social Responsibility: The extent to which this program influences Sarepta's brand perception and stakeholder relationships in the rare disease community.